Xencor has built one of the most powerful protein engineering technology platforms in the biotechnology industry. Its versatility is evidenced by our success in developing two classes of superior protein drug candidates: XmAb® antibody therapeutics and XPro® protein therapeutics. Because we can engineer the affinity and specificity of protein-protein interactions, we generate entirely new therapeutic mechanisms of action.
In collaboration with our partners—including leading pharmaceutical companies Amgen, Boehringer Ingelheim, Janssen, and Pfizer—we are selectively designing next-generation protein drug candidates with superior pharmacological properties and novel molecular compositions. Our internal pipeline of next-generation antibodies and protein therapeutics for cancer, inflammation and autoimmune disease address well understood and validated targets with improved selectivity, efficacy, safety and dosing convenience.